Pliant Therapeutics, Inc. (PLRX) — Financial statements
Income statement, balance sheet, and cash flow for Pliant Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 2↓83.7% | 10↑27.9% | 8 | |
| Cost of Revenue | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -2 | 0.00↓100.0% | 2↓83.7% | 10↑27.9% | 8 | |
| Operating Expenses | ||||||
| R&D Expenses | 109↓35.5% | 169↑32.5% | 128↑31.8% | 97↑25.0% | 78 | |
| General & Administrative Expenses | 47↓20.0% | 59↑1.9% | 58↑45.0% | 40↑45.0% | 28 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 47↓20.0% | 59↑1.9% | 58↑45.0% | 40↑45.0% | 28 | |
| Other Expenses | -8 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 148↓35.0% | 228↑23.0% | 186↑35.7% | 137↑30.2% | 105 | |
| Total Costs & Expenses | 150↓34.3% | 228↑23.0% | 186↑35.7% | 137↑30.2% | 105 | |
| Operating Results | ||||||
| Operating Income | -150↑34.3% | -228↓24.0% | -184↓44.8% | -127↓30.4% | -98 | |
| Depreciation & Amortization | 2↓20.2% | 2↑15.4% | 2↓50.0% | 4↑139.8% | 2 | |
| EBITDA | -148↑27.7% | -205↓29.7% | -158↓33.1% | -119↓24.2% | -96 | |
| EBIT | -150↑27.6% | -207↓29.5% | -160↓30.6% | -123↓26.0% | -97 | |
| Interest & Other Income | ||||||
| Net Interest Income | -3↓114.2% | 18↓20.8% | 23↑488.0% | 4↑1326.1% | 0.27 | |
| Interest Income | 0.00↓100.0% | 21↓12.4% | 24↑415.5% | 5↑1616.9% | 0.27 | |
| Interest Expense | 3↓15.4% | 3↑138.7% | 1↑60.2% | 0.79 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -21↑12.4% | -24↓415.5% | -5↓1616.9% | -0.27 | |
| Other Income / Expenses | 0.73↓96.0% | 18↓20.8% | 23↑488.0% | 4↑1326.1% | 0.27 | |
| Income Before Tax | -149↑29.0% | -210↓30.4% | -161↓30.8% | -123↓26.8% | -97 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -149↑29.0% | -210↓30.4% | -161↓30.8% | -123↓26.8% | -97 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -149↑29.0% | -210↓30.4% | -161↓30.8% | -123↓26.8% | -97 | |
| Bottom-Line Net Income | -149↑29.0% | -210↓30.4% | -161↓30.8% | -123↓26.8% | -97 | |
| EPS (Basic) | -2.43↑30.0% | -3.47↓26.2% | -2.75↑6.5% | -2.94↓8.5% | -2.71 | |
| EPS (Diluted) | -2.43↑30.0% | -3.47↓26.2% | -2.75↑6.5% | -2.94↓8.5% | -2.71 | |
| Weighted Average Shares | 61↑1.4% | 61↑3.1% | 59↑39.8% | 42↑17.2% | 36 | |
| Weighted Average Diluted Shares | 61↑1.4% | 61↑3.1% | 59↑39.8% | 42↑17.2% | 36 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.